Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
APMIS ; 123(12): 1032-9, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26547369

RESUMO

To assess the acute effects of partial splenic embolization (PSE) on portal and splanchnic hemodynamics in patients with cirrhosis. Ninety-five patients with hypersplenism were included in the study. Duplex examinations were performed before and 3 and 7 days after PSE. Portal and splanchnic hemodynamics including vessel cross-sectional area (CSA), mean flow velocities (cm/s), blood flows (mL/min), Doppler indices as portal congestion index (CI), liver vascular index, hepatic artery and superior mesenteric artery (SMA) pulsatility and resistive indices (PI and RI), were performed before and after PSE. In our study, 69 of 95 patients were males (72.6%) and 26 females (27.3%). Chronic hepatitis C virus infection was the main cause of cirrhosis (81.1%). PSE failed technically in six patients (6.3%). After PSE, both CSA and CI significantly decreased (p < 0.05 and <0.01). The portal vein velocity significantly increased (p < 0.01). The portal flow volume (892.4 ± 151 mL/min) did not show significant changes. The hepatic artery RI and PI showed a steady increase that became significant 7 days post-PSE (p < 0.05). The RI and PI of SMA increased significantly after 7 days of PSE (p < 0.05). PSE has an immediate portal decompression effect in patients with portal hypertension without reduction in portal flow. This effect on portal pressure should be investigated in future studies as a potential tool for management of acute variceal bleeding when other medical procedures fail.


Assuntos
Embolização Terapêutica , Hemodinâmica/fisiologia , Hiperesplenismo/fisiopatologia , Cirrose Hepática/terapia , Fígado/irrigação sanguínea , Circulação Esplâncnica/fisiologia , Adulto , Velocidade do Fluxo Sanguíneo/fisiologia , Feminino , Artéria Hepática/fisiopatologia , Hepatite C Crônica/etiologia , Humanos , Hiperesplenismo/etiologia , Fígado/patologia , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Masculino , Artéria Mesentérica Superior/fisiopatologia , Pessoa de Meia-Idade , Sistema Porta/fisiopatologia , Veia Porta/fisiopatologia , Adulto Jovem
2.
Dig Dis Sci ; 49(3): 379-83, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15139484

RESUMO

Symptom assessment has been proven to be less reliable than barium pill testing for success of dilation of peptic strictures. Schatzki's ring also has a high recurrence rate. Our aim here was to compare the efficacy of single dilatation with a 54-F Savary dilator and electrosurgical ring incision for symptomatic Schatzki's rings. Schatzki's ring patients who failed to pass a 12.7-mm barium pill were randomized to dilatation with a 54-F Savary dilator or four quadrant incisions with a needle knife. All received lansoprazole (30 mg) for 30 days posttreatment. Follow-up at 1, 3, 6, and 12 months used the pill test and a dysphagia score. Eleven patients (mean age, 62; median, 64) were randomized and received therapy, six with dilatation and five with incision. The ring diameter pretherapy was 9.8 +/- 1.3 mm. One patient with dilatation had a procedure-related esophageal perforation. The dysphagia score decreased (from 2.7 +/- 1.1 predilatation and 3.0 +/- 0.4 preincision) to 0 after treatment, suggesting that both therapies were equally successful. In contrast, using objective measurements with the barium pill showed that the pill failed to pass the ring in 60% at 1 month after therapy. The failure rate by 1 year was 100%. Use of an objective measure of effectiveness of treatment of symptomatic Schatzki's rings showed that neither single large-dilator dilatation nor four quadrant ring incision was a reliable and effective therapy. In the future studies, repeated dilatation may be needed to define success before long-term outcome can be accurately assessed.


Assuntos
Transtornos de Deglutição/terapia , Dilatação , Eletrocirurgia , Estenose Esofágica/terapia , Omeprazol/análogos & derivados , 2-Piridinilmetilsulfinilbenzimidazóis , Idoso , Transtornos de Deglutição/etiologia , Transtornos de Deglutição/cirurgia , Dilatação/métodos , Inibidores Enzimáticos/uso terapêutico , Estenose Esofágica/cirurgia , Humanos , Lansoprazol , Pessoa de Meia-Idade , Omeprazol/uso terapêutico , Inibidores da Bomba de Prótons , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...